Ig-related renal disease in lymphoplasmacytic disorders: An update

Seminars in Nephrology

Volumn 30, Issue 6, 2010, Pages 557-569

  Ronco, Pierre ^a,b,c   Plaisier, Emmanuelle ^a,b,c   Aucouturier, Pierre ^c,d  

^a ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^b Urgences Néphrologiques et Transplantation Rénale Hôpital Tenon 4   (France)

^c SORBONNE UNIVERSITÉ   (France)

^d CENTRE DE RECHERCHE SAINT ANTOINE   (France)

Author keywords

AL Amyloidosis; Cryoglobulinemia; Fanconi syndrome; Lymphoplasmacytic disorders; Monoclonal immunoglobulin deposition disease; Myeloma cast nephropathy

Indexed keywords

ALKYLATING AGENT; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTINEOPLASTIC AGENT; BICARBONATE; BISPHOSPHONIC ACID DERIVATIVE; BORTEZOMIB; CALCIUM; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; DEXAMETHASONE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOXORUBICIN; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; LENALIDOMIDE; MELPHALAN; PHOSPHORUS; PREDNISONE; PROTEASOME INHIBITOR; RECOMBINANT ERYTHROPOIETIN; RIBAVIRIN; RITUXIMAB; SODIUM CHLORIDE; STEROID; THALIDOMIDE; THALIDOMIDE DERIVATIVE; UNINDEXED DRUG; VINCRISTINE; VITAMIN D;

ACUTE KIDNEY FAILURE; ANEMIA; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CLINICAL FEATURE; CRYOGLOBULINEMIA; DISEASE CLASSIFICATION; DISEASE COURSE; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MEGADOSE; DRUG METABOLISM; FANCONI RENOTUBULAR SYNDROME; GLOMERULONEPHRITIS; GLOMERULOPATHY; HEMATOLOGIC DISEASE; HEMODIALYSIS; HEPATITIS C; HISTOPATHOLOGY; HUMAN; HYPERCALCEMIA; IMMUNOGLOBULIN PRODUCTION; IMMUNOPATHOLOGY; KIDNEY AMYLOIDOSIS; KIDNEY BIOPSY; KIDNEY DISEASE; KIDNEY FAILURE; KIDNEY TRANSPLANTATION; KIDNEY TUBULE DISORDER; LYMPHOPLASMACYTIC DISORDER; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; MYELOMA CAST NEPHROPATHY; NEUROTOXICITY; PATHOGENESIS; PLASMAPHERESIS; PRIORITY JOURNAL; RISK FACTOR;

HUMANS; IMMUNOGLOBULINS; KIDNEY DISEASES; KIDNEY GLOMERULUS; KIDNEY TUBULES; LYMPHOPROLIFERATIVE DISORDERS;

EID: 78649977618     PISSN: 02709295     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.semnephrol.2010.09.004     Document Type: Article

References (52)

1. Randall R.E., Williamson W.C., Mullinax F., Tung M.Y., Still W.J. Manifestations of systemic light chain deposition. Am J Med 1976, 60:293-299.
2. Leung N., Lager D.J., Gertz M.A., Wilson K., Kanakiriya S., Fervenza F.C. Long-term outcome of renal transplantation in LC deposition disease. Am J Kidney Dis 2004, 43:147-153.
3. Solomon A., Weiss D.T., Kattine A.A. Nephrotoxic potential of Bence Jones proteins. N Engl J Med 1991, 324:1845-1851.
4. Korbet S.M., Schwartz M.M. Multiple myeloma. J Am Soc Nephrol 2006, 17:2533-2545.
5. Alexanian R., Barlogie B., Dixon D. Renal failure in multiple myeloma. Pathogenesis and prognostic implications. Arch Intern Med 1990, 150:1693-1695.
6. Iványi B. Frequency of light chain deposition nephropathy relative to renal amyloidosis and Bence Jones cast nephropathy in a necropsy study of patients with myeloma. Arch Pathol Lab Med 1990, 114:986-987.
7. Rota S., Mougenot B., Baudouin B., De Meyer-Brasseur M., Lemaitre V., Michel C., et al. Multiple myeloma and severe renal failure: a clinicopathologic study of outcome and prognosis in 34 patients. Medicine (Baltimore) 1987, 66:126-137.
8. Clark W.F., Stewart A.K., Rock G.A., Sternbach M., Sutton D.M., Barrett B.J., et al. Plasma exchange when myeloma presents as acute renal failure: a randomized, controlled trial. Ann Intern Med 2005, 143:777-784.
9. Leung N., Gertz M.A., Zeldenrust S.R., Rajkumar S.V., Dispenzieri A., Fervenza F.C., et al. Improvement of cast nephropathy with plasma exchange depends on the diagnosis and on reduction of serum free light chains. Kidney Int 2008, 73:1282-1288.
10. Hutchison C.A., Bradwell A.R., Cook M., Basnayake K., Basu S., Harding S., et al. Treatment of acute renal failure secondary to multiple myeloma with chemotherapy and extended high cut-off hemodialysis. Clin J Am Soc Nephrol 2009, 4:745-754.
11. Dimopoulos M.A., Kastritis E., Rajkumar S.V. Treatment of plasma cell dyscrasias with lenalidomide. Leukemia 2008, 22:1343-1353.
12. San Miguel J.F., Schlag R., Khuageva N.K., Dimopoulos M.A., Shpilberg O., et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med 2008, 359:906-917.
13. Messiaen T., Deret S., Mougenot B., Bridoux F., Dequiedt P., Dion J.J., et al. Adult Fanconi syndrome secondary to light chain gammopathy. Clinicopathologic heterogeneity and unusual features in 11 patients. Medicine (Baltimore) 2000, 79:135-154.
14. Ma C.X., Lacy M.Q., Rompala J.F., Dispenzieri A., Rajkumar S.V., Greipp P.R., et al. Acquired Fanconi syndrome is an indolent disorder in the absence of overt multiple myeloma. Blood 2004, 104:40-42.
15. Herlitz L.C., Roglieri J., Resta R., Bhagat G., Markowitz G.S. Light chain proximal tubulopathy. Kidney Int 2009, 76:792-797.
16. Leboulleux M., Lelongt B., Mougenot B., Touchard G., Makdassi R., Rocca A., et al. Protease resistance and binding of Ig light chains in myeloma-associated tubulopathies. Kidney Int 1995, 48:72-79.
17. Kyle R.A., Greipp P.R. Amyloidosis (AL): clinical and laboratory features in 229 cases. Mayo Clin Proc 1983, 58:665-683.
18. Ronco P.M., Aucouturier P., Moulin B. Renal amyloidosis and glomerular diseases with monoclonal immunoglobulin deposition. Comprehensive clinical nephrology 2010, Mosby, London, In press. J. Feehally, R. Johnson (Eds.).
19. Katzmann J.A., Abraham R.S., Dispenzieri A., Lust J.A., Kyle R.A. Diagnostic performance of quantitative kappa and lambda free LC assays in clinical practice. Clin Chem 2005, 51:878-881.
20. Wechalekar A.D., Lachmann H.J., Goodman H.J., Bradwell A., Hawkins P.N., Gillmore J.D. AL amyloidosis associated with IgM paraproteinemia: clinical profile and treatment outcome. Blood 2008, 112:4009-4016.
21. Terrier B., Jaccard A., Harousseau J.L., Delarue R., Tournilhac O., Hunault-Berger M., et al. The clinical spectrum of IgM-related amyloidosis: a French nationwide retrospective study of 72 patients. Medicine (Baltimore) 2008, 87:99-109.
22. Lachmann H.J., Booth D.R., Booth S.E., Bybee A., Gilbertson J.A., Gillmore J.D., et al. Misdiagnosis of hereditary amyloidosis as AL (primary) amyloidosis. N Engl J Med 2002, 346:1786-1791.
23. Gertz M.A., Comenzo R., Falk R.H., Fermand J.P., Hazenberg B.P., Hawkins P.N., et al. Definition of organ involve-ment and treatment response in immunoglobulin LC amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis. Am J Hematol 2005, 79:319-328.
24. Kyle R.A., Gertz M.A., Greipp P.R., Witzig T.E., Lust J.A., Lacy M.Q., et al. A trial of three regimens for primary amyloidosis: colchicine alone, melphalan and prednisone, and melphalan, prednisone, and colchicine. N Engl J Med 1997, 336:1202-1207.
25. Skinner M., Sanchorawala V., Seldin D.C., Dember L.M., Falk R.H., Berk J.L., et al. High-dose melphalan and autologous stem-cell transplantation in patients with AL amyloidosis: an 8-year study. Ann Intern Med 2004, 140:85-93.
26. Leung N., Dispenzieri A., Fervenza F.C., Lacy M.Q., Villicana R., Cavalcante J.L., et al. Renal response after high-dose melphalan and stem cell transplantation is a favorable marker in patients with primary systemic amyloidosis. Am J Kidney Dis 2005, 46:270-277.
27. Palladini G., Perfetti V., Obici L., Caccialanza R., Semino A., Adami F., et al. Association of melphalan and high-dose dexamethasone is effective and well tolerated in patients with AL (primary) amyloidosis who are ineligible for stem cell transplantation. Blood 2004, 103:2936-2938.
28. Jaccard A., Moreau P., Leblond V., Leleu X., Benboubker L., Hermine O., et al. High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis. N Engl J Med 2007, 357:1083-1093.
29. Sanchorawala V., Skinner M., Quillen K., Finn K.T., Doros G., Seldin D.C. Long-term outcome of patients with AL amyloidosis treated with high-dose melphalan and stem-cell transplantation. Blood 2007, 110:3561-3563.
30. Kastritis E., Anagnostopoulos A., Roussou M., Toumanidis S., Pamboukas C., Migkou M., et al. Treatment of light chain (AL) amyloidosis with the combination of bortezomib and dexamethasone. Haematologica 2007, 92:1351-1358.
31. Gertz M.A., Leung N., Lacy M.Q., Dispenzieri A., Zeldenrust S.R., Hayman S.R., et al. Clinical outcome of immunoglobulin light chain amyloidosis affecting the kidney. Nephrol Dial Transplant 2009, 24:3132-3137.
32. Bollée G., Anglicheau D., Loupy A., Zuber J., Patey N., Mac Gregor D., et al. Presentation and outcome of patients with systemic amyloidosis undergoing dialysis. Clin J Am Soc Nephrol 2008, 3:375-381.
33. Mignot A., Bridoux F., Thierry A., Varnous S., Pujo M., Delcourt A., et al. Successful heart transplantation following melphalan plus dexamethasone therapy in systemic AL amyloidosis. Haematologica 2008, 93:e32-e35.
34. Ronco P., Plaisier E., Mougenot B., Aucouturier P. Immunoglobulin light (heavy)-chain deposition disease: from molecular medicine to pathophysiology-driven therapy. Clin J Am Soc Nephrol 2006, 1:1342-1350.
35. Aucouturier P., Khamlichi A.A., Touchard G., Justrabo E., Cogne M., Chauffert B., et al. Brief report: heavy-chain deposition disease. N Engl J Med 1993, 329:1389-1393.
36. Moulin B., Deret S., Mariette X., Kourilsky O., Imai H., Dupouet L., et al. Nodular glomerulosclerosis with deposition of monoclonal immunoglobulin heavy chains lacking C(H)1. J Am Soc Nephrol 1999, 10:519-528.
37. Lin J., Markowitz G.S., Valeri A.M., Kambham N., Sherman W.H., Appel G.B., et al. Renal monoclonal immunoglobulin deposition disease: the disease spectrum. J Am Soc Nephrol 2001, 12:1482-1492.
38. Pozzi C., D'Amico M., Fogazzi G.B., Curioni S., Ferrario F., Pasquali S., et al. Light chain deposition disease with renal involvement: clinical characteristics and prognostic factors. Am J Kidney Dis 2003, 42:1154-1163.
39. Royer B., Arnulf B., Martinez F., Roy L., Flageul B., Etienne I., et al. High dose chemotherapy in light chain or light and heavy chain deposition disease. Kidney Int 2004, 65:642-648.
40. Nasr S.H., Satoskar A., Markowitz G.S., Valeri A.M., Appel G.B., Stokes M.B., et al. Proliferative glomerulonephritis with monoclonal IgG deposits. J Am Soc Nephrol 2009, 20:2055-2064.
41. Alpers C.E., Kowalewska J. Fibrillary glomerulonephritis and immunotactoid glomerulopathy. J Am Soc Nephrol 2008, 19:34-37.
42. Bridoux F., Hugue V., Coldefy O., Goujon J.M., Bauwens M., Sechet A., et al. Fibrillary glomerulonephritis and immunotactoid (microtubular) glomerulopathy are associated with distinct immunologic features. Kidney Int 2002, 62:1764-1775.
43. Rosenstock J.L., Markowitz G.S., Valeri A.M., Sacchi G., Appel G.B., D'Agati V.D. Fibrillary and immunotactoid glomerulonephritis: distinct entities with different clinical and pathologic features. Kidney Int 2003, 63:1450-1461.
44. Brouet J.C., Clauvel J.P., Danon F., Klein M., Seligmann M. Biologic and clinical significance of cryoglobulins. A report of 86 cases. Am J Med 1974, 57:775-788.
45. Saadoun D., Landau D.A., Calabrese L.H., Cacoub P.P. Hepatitis C-associated mixed cryoglobulinaemia: a crossroad between autoimmunity and lymphoproliferation. Rheumatology (Oxford) 2007, 46:1234-1242.
46. Charles E.D., Dustin L.B. Hepatitis C virus-induced cryoglobulinemia. Kidney Int 2009, 76:818-824.
47. Matignon M., Cacoub P., Colombat M., Saadoun D., Brocheriou I., Mougenot B., et al. Clinical and morphologic spectrum of renal involvement in patients with mixed cryoglobulinemia without evidence of hepatitis C virus infection. Medicine (Baltimore) 2009, 88:341-348.
48. Saadoun D., Sellam J., Ghillani-Dalbin P., Crecel R., Piette J.C., Cacoub P. Increased risks of lymphoma and death among patients with non-hepatitis C virus-related mixed cryoglobulinemia. Arch Intern Med 2006, 166:2101-2108.
49. Beddhu S., Bastacky S., Johnson J.P. The clinical and morphologic spectrum of renal cryoglobulinemia. Medicine (Baltimore) 2002, 81:398-409.
50. Roccatello D., Fornasieri A., Giachino O., Rossi D., Beltrame A., Banfi G., et al. Multicenter study on hepatitis C virus-related cryoglobulinemic glomerulonephritis. Am J Kidney Dis 2007, 49:69-82.
51. Sène D., Ghillani-Dalbin P., Amoura Z., Musset L., Cacoub P. Rituximab may form a complex with IgMkappa mixed cryoglobulin and induce severe systemic reactions in patients with hepatitis C virus-induced vasculitis. Arthritis Rheum 2009, 60:3848-3855.
52. Audard V., Georges B., Vanhille P., Toly C., Deroure B., Fakhouri F., et al. Renal lesions associated with IgM-secreting monoclonal proliferations: revisiting the disease spectrum. Clin J Am Soc Nephrol 2008, 3:1339-1349.